NGF/γ-IFN inhibits androgen-independent prostate cancer and reverses androgen receptor function through downregulation of FGFR2 and decrease in cancer stem cells

Stem Cells and Development

Volumn 21, Issue 18, 2012, Pages 3372-3380

  Chen, Wei ^a   Wang, Guo Min ^a   Guo, Jian Ming ^a   Sun, Li An ^a   Wang, Hang ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUTAMIDE; GAMMA INTERFERON; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; NERVE GROWTH FACTOR; NEUTRALIZING ANTIBODY; WNT PROTEIN;

ANDROGEN INDEPENDENT PROSTATE CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CANCER STEM CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; DOWN-REGULATION; HUMANS; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NERVE GROWTH FACTOR; PROSTATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROLOGOUS; WNT1 PROTEIN; WNT2 PROTEIN;

ANIMALIA;

EID: 84870830982     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0121     Document Type: Article

References (37)

1. Labrie F, A Dupont, L Cusan, J Gomez, J Emond and G Monfette. (1990). Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience. J Steroid Biochem 37:943-950.
2. Huggins C and CV Hodges. (2002). Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 168:9-12.
3. Macfarlane RJ and KN Chi. (2010). Research in castrationresistant prostate cancer: what does the future hold? Curr Oncol Suppl 2:80-86.
4. Scher HI, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26:1148-1159.
5. Heidenreich A, G Aus, M Bolla, S Joniau, VB Matveev, HP Schmid, et al. (2008). European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 53:68-80.
6. Pajonk F, E Vlashi and WH McBride. (2010). Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28:639-648.
7. Silvestre DC, JR Pineda, F Hoffschir, JM Studler, MA Mouthon, F Pflumio, et al. (2011). Alternative lengthening of telomeres in human glioma stem cells. Stem Cells 29: 440-451
8. Taipale J and PA Beachy. (2001). The Hedgehog and Wnt signalling pathways in cancer. Nature 411:349-354.
9. Rizzo S, JM Hersey, P Mellor, W Dai, A Santos-Silva, D Liber, et al. (2011). Ovarian cancer stem cell-like side populations are enriched following chemotherapyy and overexpress EZH2. Mol Cancer Ther 10:325-335.
10. Yuki K, A Natsume, H Yokoyama, Y Kondo, M Ohno, T Kato, et al. (2009). Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett 284:71-79.
11. Korkaya H and MS Wicha. (2009). HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 15:1845-1847.
12. Chou YF, HH Chen, M Eijpe, A Yabuuchi, JG Chenoweth, P Tesar, et al. (2008). The growth factor environment defines distinct pluripotent ground states in novel blastocystderived stem cells. Cell 135:449-461.
13. DeSchryver-Kecskemeti K, K Balogh and E Neet. (1987). Nerve growth factor and the concept of neural-epithelial interactions. Arch Pathol Lab Med 111:833-835.
14. Graham CW, JH Lynch and D Djakiew. (1992). Distribution of nerve growth factor like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 147:1444-1447.
15. Zhu ZW, H Friess, L Wang, FF Di Mola, A Zimmermann and MW Buchler. (2000). Down regulation of nerve growth factor in poorly differentiated and advanced human esophageal cancer. Anticancer Res 20:125-132.
16. Missale C, F Boroni, M Losa, M Giovanelli, A Zanellato, R Dal Toso, et al. (1993). Nerve growth factor suppresses the transforming phenotype of f human prolactinomas. Proc Natl Acad Sci U S A 90:7961-7965.
17. Missale C, A Codignola, S Sigala, A Finardi, M Paez-Pereda, E Sher, et al. (1998). Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci U S A 95:5366-5371.
18. Tsim TY, EY Wong, MS Leung and CC Wong. (2004). Expression of axon guidance molecules and their related genes during development and sexual differentiation of the olfactory bulb in rats. Neuroscience 123:951-965.
19. Arsenijevic Y and E Tribollet. (1998). Region-specific effect of testosterone on oxytocin receptor binding in the brain of the aged rat. Brain Res 78:5167-5170.
20. Sigala S, N Tognazzi, MC Rizzetti, I Faraoni, C Missale, E Bonmassar, et al. (2002). Nerve growth factor induces the reexpression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. Eur J Endocrinol 147:407-415.
21. Fisher AD, MA Crowe, EM O'Nuallá in, ML Monaghan, JA Larkin, P O'Kiely, et al. (1997). Effects of cortisol on in vitro interferon-gamma production, acute-phase proteins, growth, and feed intake in a calf castration model. J Anim Sci 75: 1041-1047.
22. Untergasser G, E Plas, G Pfister, E Heinrich and P Berger. (2005). Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells. Prostate 64:419-429.
23. Shikata A, T Shikata, Y Sotozono, H Hosoi, T Matsumura, T Sugimoto, et al. (2000). Neuronal differentiation in human neuroblastoma cells by nerve growth factor following TrkA up-regulation by interferon-gamma. Med Pediatr Oncol 34: 394-401.
24. Wei C, W Guomin, L Yujun and Q Ruizhe. (2007). Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol Ther 6:763-768.
25. Collins AT, FK Habib, NJ Maitland and DE Neal. (2001). Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)- integrin expression. J Cell Sci 114:3865-3872.
26. Collins AT, PA Berry, C Hyde, MJ Stower and NJ Maitland. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951.
27. Liu AY. (2000). Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60:3429-3434.
28. Stowe RP, MK Peek, MP Cutchin and JS Goodwin. (2010). Plasma cytokine levels in a population-based study: relation to age and ethnicity. J Gerontol A-Biol 65:429-433.
29. Blasco MA. (2007). Telomere length, stem cells and aging. Nat Chem Biol 3:640-649.
30. Flores I, ML Cayuela and MA Blasco. (2005). Effects of telomerase and telomere length on epidermal stem cell behavior. Science 309:1253-1256.
31. Park JI, AS Venteicher, JY Hong, J Choi, S Jun, M Shkreli, et al. (2009). Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460:66-72.
32. Harimoto N, K Taguchi, K Shirabe, E Adachi, Y Sakaguchi, Y Toh, et al. (2010). The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma. Oncology 78:361-368.
33. Zhang Y, H Wang, S Toratani, JD Sato, M Kan, WL McKeehan, et al. (2001). Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci U S A 98:11336-11340.
34. Visco V, FA Bava, F d'Alessandro, M Cavallini, V Ziparo and MR Torrisi. (2009). Human colon fibroblasts induce differentiation and proliferation of intestinal epithelial cells through the direct paracrine action of keratinocyte growth factor. J Cell Physiol 220:204-213.
35. Yoshino M, T Ishiwata, M Watanabe, T Matsunobu, O Komine, Y Ono, et al. (2007). Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol 31:721-728.
36. Heer R, AT Collins, CN Robson, BK Shenton and HY Leung. (2006). KGF suppresses alpha2beta1 integrin function and promotes differentiation of the transient amplifying population in human prostatic epithelium. J Cell Sci 119:1416-1424.
37. Arianayagam R, M Arianayagam, S McGrath and P Rashid. (2010). Androgen deficiency in the aging man. Aust Fam Physician 39:752-755.